Toxin-Antitoxin Nucleic Acid Constructs for Selective Cancer Cell Killing

The patent changes the therapeutic parameter from targeting EGFR (which fails in KRAS-mutated cancers) to targeting the RAS pathway directly by exploiting its hyperactivity. This parameter change allows the therapy to be effective specifically in cancers with activated RAS signaling, overcoming the resistance problem that plagues anti-EGFR therapies in this patient population.

The patent applies local quality by creating a therapy that specifically targets cells with hyperactive RAS pathways while sparing normal cells with wild-type RAS. The selective toxicity is achieved through the dual-promoter system that responds differently to RAS signaling intensity, allowing the same therapeutic agent to have different effects in different cell types based on their RAS activity level.

The patent implements local quality through a dual-promoter system where the toxin gene is controlled by a cancer-specific promoter (responding to hyperactive RAS) and the anti-toxin gene is controlled by a constitutive promoter. This creates a local difference in gene expression patterns that allows selective toxicity: cancer cells with the transgene express only the toxin, while normal cells expressing both transgenes produce the anti-toxin that neutralizes it.

The anti-toxin acts as an intermediary that mediates protection of normal cells. When both toxin and anti-toxin are expressed (as in normal cells receiving the dual construct), the anti-toxin neutralizes the toxin's harmful effects. This intermediary mechanism allows the therapy to be delivered systemically while still protecting normal tissues from damage.

The patent uses local quality by creating spatial and functional differentiation in toxin expression. The toxin is expressed at high levels only in cells where the cancer-specific promoter is activated (hyperactive RAS cells), while in normal cells the same promoter remains inactive. The anti-toxin is expressed constitutively in all cells, providing a protective buffer that prevents systemic toxicity while allowing high local toxin concentrations in cancer cells.

The patent applies preliminary anti-action by pre-equipping all cells with the anti-toxin through the constitutive promoter. This creates a protective mechanism in advance that neutralizes any toxin that might be produced, preventing harm to normal cells. In cancer cells, the overwhelming toxin production from the activated promoter exceeds the protective capacity of the anti-toxin, resulting in selective cell death.